Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate‐to‐severe atopic dermatitis in adults: A multicentre real‐world study
Elena Pezzolo, Donatella Schena, Alessio Gambardella, Mariateresa Rossi, Francesca Barei, Piergiacomo Calzavara‐Pinton, Giampiero Girolomoni, Luigi Naldi, Silvia Mariel Ferrucci
Abstract
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to the privacy or ethical restrictions.
Topics & Concepts
MedicineAtopic dermatitisDermatologyPediatricsDermatology and Skin DiseasesAllergic Rhinitis and SensitizationAsthma and respiratory diseases